These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 15968890)
1. Microcirculatory and clinical effects of serial percutaneous application of carbon dioxide in primary and secondary Raynaud's phenomenon. Schmidt J; Monnet P; Normand B; Fabry R Vasa; 2005 May; 34(2):93-100. PubMed ID: 15968890 [TBL] [Abstract][Full Text] [Related]
2. Clinical and microcirculatory effects of transcutaneous CO2 therapy in intermittent claudication. Randomized double-blind clinical trial with a parallel design. Fabry R; Monnet P; Schmidt J; Lusson JR; Carpentier PH; Baguet JC; Dubray C Vasa; 2009 Aug; 38(3):213-24. PubMed ID: 19736632 [TBL] [Abstract][Full Text] [Related]
3. Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome: a randomised trial. Tucker AT; Pearson RM; Cooke ED; Benjamin N Lancet; 1999 Nov; 354(9191):1670-5. PubMed ID: 10568568 [TBL] [Abstract][Full Text] [Related]
4. Laser Doppler-recorded venoarteriolar reflex in Raynaud's phenomenon. Stoyneva Z Auton Neurosci; 2004 Nov; 116(1-2):62-8. PubMed ID: 15556839 [TBL] [Abstract][Full Text] [Related]
5. The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon. Friedman EA; Harris PA; Wood AJ; Stein CM; Kurnik D Clin Pharmacol Ther; 2007 Apr; 81(4):503-9. PubMed ID: 17301734 [TBL] [Abstract][Full Text] [Related]
6. [Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial]. Correa MJ; Mariz HA; Andrade LE; Kayser C Rev Bras Reumatol; 2014; 54(6):452-8. PubMed ID: 25458027 [TBL] [Abstract][Full Text] [Related]
7. Local cold exposure test as therapy control in patients with Raynaud's phenomenon: comparison between laser Doppler fluxmetry and simultaneous red blood cell velocity measurements in nailfold capillaries. Hahn M; Klyscz T; Jünger M; Rassner G Br J Dermatol; 1995 Nov; 133(5):704-9. PubMed ID: 8555020 [TBL] [Abstract][Full Text] [Related]
8. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170 [TBL] [Abstract][Full Text] [Related]
9. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Fries R; Shariat K; von Wilmowsky H; Böhm M Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885 [TBL] [Abstract][Full Text] [Related]
10. Acute effect of topical minoxidil on digital blood flow in patients with Raynaud's phenomenon. Whitmore SE; Wigley FM; Wise RA J Rheumatol; 1995 Jan; 22(1):50-4. PubMed ID: 7699682 [TBL] [Abstract][Full Text] [Related]
11. Laser Doppler flowmeter and standardized thermal test in normals and Raynaud's phenomenon. Boccalon HJ; Marguery MC; Ginestet MC; Puel PF Int Angiol; 1987; 6(2):107-18. PubMed ID: 3323348 [TBL] [Abstract][Full Text] [Related]
12. Quantitative study of the effects of Ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled investigation and an additional long term open trial. van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH Microcirc Endothelium Lymphatics; 1985; 2(6):657-85. PubMed ID: 2942753 [TBL] [Abstract][Full Text] [Related]
13. The relationship between subjective vasospastic complaints and finger blood flow measurements in Raynaud's phenomenon. Leesmans E; Bartelink ML; Wollersheim H; Thien T Neth J Med; 1993 Aug; 43(1-2):13-7. PubMed ID: 8232689 [TBL] [Abstract][Full Text] [Related]
14. Laser Doppler skin perfusion pressure in the assessment of Raynaud's phenomenon. Kanetaka T; Komiyama T; Onozuka A; Miyata T; Shigematsu H Eur J Vasc Endovasc Surg; 2004 Apr; 27(4):414-6. PubMed ID: 15015193 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular responses evoked by mild cool stimuli in primary Raynaud's disease: the role of endothelin. Edwards CM; Marshall JM; Pugh M Clin Sci (Lond); 1999 Jun; 96(6):577-88. PubMed ID: 10334963 [TBL] [Abstract][Full Text] [Related]
16. The effectiveness of ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled study. van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH Int Angiol; 1987; 6(3):313-22. PubMed ID: 3329207 [TBL] [Abstract][Full Text] [Related]
17. The response of skin perfusion and of rheological and immunological variables to intravenous prostanoid administration in Raynaud's phenomenon secondary to collagenosis. Drinda S; Neumann T; Pöhlmann G; Vogelsang H; Stein G; Wolf G; Hein G Vasa; 2005 Nov; 34(4):243-9. PubMed ID: 16363279 [TBL] [Abstract][Full Text] [Related]
18. Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon. French Microcirculation Society Multicentre Group for the Study of Vascular Acrosyndromes. Vayssairat M J Rheumatol; 1996 Nov; 23(11):1917-20. PubMed ID: 8923366 [TBL] [Abstract][Full Text] [Related]
19. Low level laser therapy in primary Raynaud's phenomenon--results of a placebo controlled, double blind intervention study. Hirschl M; Katzenschlager R; Francesconi C; Kundi M J Rheumatol; 2004 Dec; 31(12):2408-12. PubMed ID: 15570642 [TBL] [Abstract][Full Text] [Related]
20. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]